Influenza-associated pulmonary aspergillosis (IAPA) is a feared complication in patients with influenza tracheobronchitis, especially those receiving corticosteroids. Herein, we established a novel IAPA mouse model with low-inoculum Aspergillus infection and compared outcomes in mice with and without cortisone acetate (CA) immunosuppression. CA was an independent predictor of increased morbidity/mortality in mice with IAPA. Early antifungal treatment with liposomal amphotericin B was pivotal to improve IAPA outcomes in CA-immunosuppressed mice, even after prior antiviral therapy with oseltamivir. In summary, our model recapitulates key clinical features of IAPA and provides a robust preclinical platform to study the pathogenesis and treatment of IAPA.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10319956PMC
http://dx.doi.org/10.1093/infdis/jiad001DOI Listing

Publication Analysis

Top Keywords

mouse model
8
study pathogenesis
8
influenza-associated pulmonary
8
pulmonary aspergillosis
8
iapa
6
development corticosteroid-immunosuppressed
4
corticosteroid-immunosuppressed mouse
4
model study
4
pathogenesis therapy
4
therapy influenza-associated
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!